Aller au contenu principal
Accès ouvert déclaré 2022 article

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

12Citations signalées, ce qui n’est pas une note de qualité
50Institutions déclarées
10Pays d’affiliation déclarés

Rattachement africain : gb, fr, de, es, ch, pt, ro, us, dk, ru. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

PURPOSE Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early intervention are critical. We sought to identify features of COVID-19 disease in patients with cancer predicting severe disease and build a decision support online tool, COVID-19 Risk in Oncology Evaluation Tool (CORONET). METHODS Patients with active cancer (stage I-IV) and laboratory-confirmed COVID-19 disease presenting to hospitals worldwide were included. Discharge (within 24 hours), admission (≥ 24 hours inpatient), oxygen (O 2 ) requirement, and death were combined in a 0-3 point severity scale. Association of features with outcomes were investigated using Lasso regression and Random Forest combined with Shapley Additive Explanations. The CORONET model was then examined in the entire cohort to build an online CORONET decision support tool. Admission and severe disease thresholds were established through pragmatically defined cost functions. Finally, the CORONET model was validated on an external cohort. RESULTS The model development data set comprised 920 patients, with median age 70 (range 5-99) years, 56% males, 44% females, and 81% solid versus 19% hematologic cancers. In derivation, Random Forest demonstrated superior performance over Lasso with lower mean squared error (0.801 v 0.807) and was selected for development. During validation (n = 282 patients), the performance of CORONET varied depending on the country cohort. CORONET cutoffs for admission and mortality of 1.0 and 2.3 were established. The CORONET decision support tool recommended admission for 95% of patients eventually requiring oxygen and 97% of those who died (94% and 98% in validation, respectively). The specificity for mortality prediction was 92% and 83% in derivation and validation, respectively. Shapley Additive Explanations revealed that National Early Warning Score 2, C-reactive protein, and albumin were the most important features contributing to COVID-19 severity prediction in patients with cancer at time of hospital presentation. CONCLUSION CORONET, a decision support tool validated in health care systems worldwide, can aid admission decisions and predict COVID-19 severity in patients with cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
Date Crossref
01/05/2022
Éditeur
American Society of Clinical Oncology (ASCO)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

University of ManchesterThe Christie NHS Foundation TrustCancer Research UK Manchester InstituteInstitut Gustave RoussyPhysikalisch-Technische BundesanstaltAsklepios Klinik AltonaWeston Park Cancer CentreSheffield Teaching Hospitals NHS Foundation TrustUniversity of DundeeNinewells HospitalCentre National de la Recherche ScientifiqueInsermAix-Marseille UniversitéCentre de Recherche en Cancérologie de MarseilleUniversité Paris-SaclayClatterbridge Cancer Centre NHS Foundation TrustHospital General Universitario Gregorio MarañónEuropean Society for Medical OncologyAlgarve Biomedical CenterUniversidade Nova de LisboaSouthampton General HospitalUniversity Hospital Southampton NHS Foundation TrustInstitutul Clinic FundeniLahey Medical CenterUniversity Hospitals of Leicester NHS TrustUniversity Hospitals Plymouth NHS TrustOdense University HospitalRoyal Marsden NHS Foundation TrustCopenhagen University HospitalRigshospitaletInstitute of Cancer ResearchRoyal Preston HospitalUniversity Hospitals Bristol NHS Foundation TrustAalborg University HospitalUniversity College London Hospitals NHS Foundation TrustMRC Clinical Trials Unit at UCLUniversity College LondonUniversity of LiverpoolSIB Swiss Institute of BioinformaticsCentre Hospitalier Universitaire VaudoisHospital Universitario Infanta LeonorUniversity of BristolUniversité Paris Sciences et LettresInstitut CurieRoyal Cornwall Hospital TrustSechenov UniversityRoyal Liverpool University HospitalUniversity of LeicesterHospital Universitario La PazCancer Research UK

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

COVID-19 and healthcare impactsCOVID-19 Clinical Research StudiesEconomic and Financial Impacts of Cancer

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.